References

American Thoracic Society. (2012). Pathogenesis. Retrieved June, 2012, from http://www.thoracic.org/clinical/copd-guidelines/for-health-professionals/pathology-pathogenesis-and-pathophysiology/pathogenesis.php

Bostock-Cox, B. (2010).  Prescribing inhaled therapies in the treatment of COPD. Nurse Prescribing, 8(12), 571-577.

Cerveri, I., & Brusasco, V. (2010). Revisited role for mucus hypersecretion in the pathogenesis of COPD. European Respiratory Review, 19(116), 109-112.

Decramer, M., et al.  (2008). COPD as a Lung Disease with Systemic Consequences. Clinical Impact, Mechanisms, and Potential for Early Intervention. COPD, 5(4):235–56.

Dekhuijzen, P. N., Aben, K. K., Dekker, I., Aarts, L. P., Wielders, P. L., Van Herwaarden, C. L., & Bast, A. (1996). Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care, 154(3), 813-816.

Ferrara, A. (2011). Chronic obstructive pulmonary disease. Radiologic Technology, 82(3), 245-267.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2011) Global
strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease. National Guideline Clearinghouse. Retrieved on July 5th,
2012 from www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf

Gross, P., Babyak, M. A., Tolker, E., & Kaschak, M. (1964). Enzymatically produced pulmonary emphysema: A preliminary report. Journal of Occupational and Environmental Medicine, 6(12), 481-484.

Greener, M. (2011). Roflumilast: A new agent for the treatment of COPD. Nurse Prescribing, 9(4), 167-171.

Gullick, J., and Stainton, M.C. (2008). Living with chronic obstructive pulmonary disease: Developing conscious body management in a shrinking life-world.  Journal of Advanced Nursing, 64(6), 605–14.

Hanania, N.A., Müllerova, H., Locantore, N.W., Vestbo, J., Watkins, M.L., Wouters, E.F., et al. (2011). Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. American Journal of  Respiratory Critical Care Medicine, 183(5), 604-611.

Higginson, R. (2010). COPD: Pathophysiology and treatment. Nurse Prescribing, 8(3), 102-110.

Hongjun, J., Webb-Robertson, B., Peterson, E. S., Tan, R., Bigelow, D. J., Scholand, M., & ... Zangar, R. C. (2011). Smoking, COPD, and 3-nitrotyrosine levels of plasma proteins. Environmental Health Perspectives, 119(9), 1314-1320.

Hudd, T., R., & Zaiken, K. (2011). Management of chronic obstructive pulmonary disease: An emphasis on recently approved medications and products in the pipeline. Formulary, 46(9), 374-393.

Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., et al. (2010)
Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England
Journal of Medicine, 363(12), 1128-1138.

Janoff, A., Sloan, B., Weinbaum, G., Damiano, V., Sandhaus, R. A., Elias, J., & Kimbel, P. (1977). Experimental emphysema induced with purified human neutrophil elastase: Tissue localization of the instilled protease. The American Review of Respiratory Disease, 115(3), 461-478.

Martinez, F.J. Lung volume reduction surgery in COPD. (2010). In: UpToDate, Stoller, J.K. (ed.). Retrieved June, 2012, from www.uptodate.com

Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD). Retrieved May, 2012, from  http://pda.rnao.ca/guideline-content/20

O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. (2008). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Canadian Respiratory Journal: Journal of the Canadian Thoracic Society, 15(Suppl A), 1A-8A.

Papi, A., Luppi, F., Franco, F., & Fabbri, L. M. (2005). Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 3(3), 245-251.

Park, J. W., Ryter, S. W., & Choi, A. M. K. (2007). Functional significance of apoptosis in chronic obstructive pulmonary disease. Journal of Chronic Obstructive Pulmonary Disease, 4(4), 347-353.

Rennard, S. I. (2011). COPD heterogeneity: What this will mean in practice. Respiratory Care, 56(8), 1181-1187.

Roth, M. (2008). Pathogenesis of COPD: Part III, inflammation in COPD. International Journal of Tuberculosis and Lung Disease, 12(4), 375-380.

Scanlon, P. D. (2004). The pathogenesis and pathology of COPD: Identifying risk factors and improving morbidity and mortality. Advanced Studies in Medicine, 4(10A), S744-S749.

Schiffman, G. (2012). Chronic Obstructive Pulmonary Disease. Retrieved on July
5th, 2012 from
www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/article.htm

Sommerhoff, C. P., Nadel, J. A., Basbaum, C. B., & Caughey, G. H. (1990). Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. Journal of Clinical Investigation, 85(3), 682-689.

Spurzem, J. R., Stephen, I., & Rennard, S. I. (2005). Pathogenesis of COPD. Seminars in Respiratory and Critical Care Medicine, 26(2), 142-153.

Tetley, T. D. (2002). Macrophages and the pathogenesis of COPD. Chest, 121(5 Suppl.), 156S-159S.

Viegi, G., Scognamiglio, A., Baldacci, S., Pistelli, F., & Carrozzi, L. (2001). Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration, 68(1), 4-19.